Recent published studies have implicated a role for Syk in determining the response to taxane treatment in human ovarian cancer cell models [8], with one study demonstrating improved paclitaxel activity in taxane-selected variants treated with the Syk inhibitor R406 [9]. This evidence concerns the gene SYK and ovarian cancer.